Healthcare provider profile · identity verified

Robert Steven Legrow, M.D.

Family Practice · WATERTOWN, WI · NPI 1013908771

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	844	221
Levothyroxine Sodium	Levothyroxine Sodium	354	79
Omeprazole	Omeprazole	327	85
Losartan Potassium	Losartan Potassium	311	79
Amlodipine Besylate	Amlodipine Besylate	308	84
Hydrochlorothiazide	Hydrochlorothiazide	288	74
Lisinopril	Lisinopril	270	72
Metformin Hcl	Metformin Hcl	215	50
Metoprolol Succinate	Metoprolol Succinate	201	51
Gabapentin	Gabapentin	179	49
Allopurinol	Allopurinol	177	49
Metformin Hcl Er	Metformin Hcl	174	54
Rosuvastatin Calcium	Rosuvastatin Calcium	166	54
Furosemide	Furosemide	164	54
Sertraline Hcl	Sertraline Hcl	163	47
Tamsulosin Hcl	Tamsulosin Hcl	148	39
Metoprolol Tartrate	Metoprolol Tartrate	129	34
Pantoprazole Sodium	Pantoprazole Sodium	119	33
Fluticasone Propionate	Fluticasone Propionate	113	45
Simvastatin	Simvastatin	112	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	109	34
Ozempic	Semaglutide	103	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	99	28
Pravastatin Sodium	Pravastatin Sodium	89	21
Atenolol	Atenolol	88	23
Mounjaro	Tirzepatide	87	18
Venlafaxine Hcl Er	Venlafaxine Hcl	84	16
Potassium Chloride	Potassium Chloride	81	20
Warfarin Sodium	Warfarin Sodium	76	22
Clopidogrel	Clopidogrel Bisulfate	75	21
Carvedilol	Carvedilol	71	22
Finasteride	Finasteride	70	19
Glipizide Er	Glipizide	70	20
Trazodone Hcl	Trazodone Hcl	70	21
Trulicity	Dulaglutide	70	13
Bupropion Xl	Bupropion Hcl	62	13
Donepezil Hcl	Donepezil Hcl	62	14
Meloxicam	Meloxicam	62	23
Alendronate Sodium	Alendronate Sodium	61	17
Albuterol Sulfate Hfa	Albuterol Sulfate	58	30
Famotidine	Famotidine	55	21
Lorazepam	Lorazepam	50	11
Chlorthalidone	Chlorthalidone	48	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	47	suppressed
Spironolactone	Spironolactone	46	14
Prednisone	Prednisone	45	37
Escitalopram Oxalate	Escitalopram Oxalate	42	11
Propranolol Hcl	Propranolol Hcl	42	suppressed
Eliquis	Apixaban	40	suppressed
Alprazolam	Alprazolam	39	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	11
Synthroid	Levothyroxine Sodium	36	suppressed
Glipizide	Glipizide	35	11
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	11
Enalapril Maleate	Enalapril Maleate	33	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Tramadol Hcl	Tramadol Hcl	31	17
Montelukast Sodium	Montelukast Sodium	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	20
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	29	suppressed
Benazepril Hcl	Benazepril Hcl	28	suppressed
Nifedipine Er	Nifedipine	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Memantine Hcl	Memantine Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Glimepiride	Glimepiride	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	14
Valsartan	Valsartan	24	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	23	15
Xarelto	Rivaroxaban	23	suppressed
Baclofen	Baclofen	22	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	22	suppressed
Aripiprazole	Aripiprazole	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Topiramate	Topiramate	19	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	19	suppressed
Cephalexin	Cephalexin	18	16
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	16
Nystatin	Nystatin	17	13
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Propranolol Hcl Er	Propranolol Hcl	17	suppressed
Myrbetriq	Mirabegron	16	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Ramelteon	Ramelteon	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Sulfasalazine	Sulfasalazine	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Letrozole	Letrozole	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Estradiol	Estradiol	11	suppressed
Lactulose	Lactulose	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error